“We applaud the members of the Senate Judiciary Committee for voting the CREATES Act out of committee and advancing this bipartisan legislation one step closer to becoming law.
“The CREATES Act will put an end to anticompetitive practices used by some drug manufacturers to thwart generic competition and artificially keep drug prices high. It is a market-based solution that will help speed generics and biosimilar competition to the marketplace and provide real relief for patients who cannot afford the drugs on which they depend. The problem is the price, and more competition is the proven solution.
“Chairman Grassley, Ranking Member Feinstein, and their 27 bipartisan colleagues who are co-sponsors of the CREATES Act, deserve real credit for their work to reduce out-of-control drug prices for all Americans.”